Skip to Content

'
Kenneth R. Hess, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Associate Professor, Department of Biostatistics, Texas A & M University, College Station, TX
Adjunct Associate Professor, Statistics, Rice University, Houston, TX
Regular Member of Graduate Faculty, The University of Texas Houston Health Science Center, Houston, TX

Research Interests

  • Survival data analysis
  • Statistical consulting and education
  • Phase II oncology trial designs
  • Prognostic factor studies
  • Supervised analysis with high-throughput data such as mircoarrays
  • Cross-validation and related issues

Education & Training

Degree-Granting Education

1992 The University of Texas School of Public Health, Houston, TX, PHD, Biometry
1986 The University of Texas School of Public Health, Houston, TX, MS, Biometry
1982 Rice University, Houston, TX, BS, Electrical Engineering

Selected Publications

Peer-Reviewed Original Research Articles

1. González L, Magno P, Ortiz AP, Ortiz-Ortiz K, Hess K, Nogueras-González GM, Suárez E. Esophageal Cancer incidence rates by histological type and overall: Puerto Rico versus the United States Surveillance, Epidemiology, and End Results population 1992-2005. Cancer Epidemiol 37(1):5-10, 2/2013. e-Pub 10/11/2012. PMCID: PMC3545418.
2. Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat DOI 10.1007/s10549-012-2366-0(2):449-55, 1/2013. e-Pub 12/6/2012. PMCID: PMC3544467.
3. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 1/2013. e-Pub 12/15/2012. PMCID: PMC3867793.
4. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget 4(1):153-62, 1/2013. e-Pub 1/27/2013. PMCID: PMC3702215.
5. Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK. Phospho-histone H3(pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary 15(4):556-61, 12/2012. e-Pub 11/2011. PMCID: PMC3852837.
6. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progressionon first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat DOI 10.1007/s10549-012-2194-2(2):619-27, 9/2012. e-Pub 8/14/2012. PMID: 22890751.
7. Liedtke C, Packeisen J, Hess KR, Vogt U, Kiesel L, Kersting C, Korsching E, Brandt B, Buerger H. Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. Eur J Cancer 48(13):2066-74, 9/2012. e-Pub 9/13/2011. PMID: 21920731.
8. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14):3599-606, 7/15/2012. e-Pub 11/15/2011. PMID: 22086614.
9. Dong X, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog 51(6):491-9, 6/2012. e-Pub 6/16/2011. PMCID: PMC3179809.
10. Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol 36(2):206-11, 4/2012. e-Pub 8/17/2011. PMID: 21852217.
11. Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, Hess K, Fuller GN, Zhang W. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci U S A 109(9):3475-80, 2/28/2012. e-Pub 2/15/2012. PMCID: PMC3295320.
12. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306(14):1557-65, 10/12/2011. PMID: 21990299.
13. Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cncer Res Treat. e-Pub 6/2011.
14. Dong X, Li Y, Chang P, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila) 4(5):758-66, 5/2011. e-Pub 3/16/2011. PMID: 21411499.
15. Dong X, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer 117(3):480-91, 2/1/2011. e-Pub 9/15/2010. PMCID: PMC3961843.
16. Dong X, Li Y, Hess KR, Abbruzzese JL, Li D. DNA Mismatch Repair Gene Polymorphisms Affect Survival in Pancreatic Cancer. Oncologist. e-Pub 1/6/2011. PMID: 21212431.
17. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3):R67, 2011. e-Pub 6/15/2011. PMCID: PMC3218956.
18. Hu Y Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, Hamamura M, Yu L, Hess KR, Tromberg BJ, Linskey ME and Zhou YI. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Molecular Cancer 10(123), 2011.
19. Hess KR, Wei C, Qi Y, Iwamoto T, Symmans WF, Pusztai L. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics 12(463), 2011. PMCID: PMC3245512.
20. Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol 12(11):1167-1172, 11/2010. e-Pub 8/20/2010. PMCID: PMC3098026.
21. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clin Cancer Res 16(21):5351-61, 11/2010. e-Pub 9/2010. NIHMSID: NIHMS241608.
22. Hess KR. Comparing Survival Curves Using an Easy to Interpret Statistic. Clin Cancer Res 16(20):4912-4913, 10/2010. e-Pub 8/2010. PMID: 20732962.
23. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like Growth Factor Axis Gene Polymorphisms and Clinical Outcomes in Pancreatic Cancer. Gastroenterology 139(2):464-73, 473.e1-3, 8/2010. e-Pub 4/21/2010. PMCID: PMC2910789.
24. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R, Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D, Thierry-Mieg J, Thodima V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q, Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, Fulmer-Smentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J, Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G, Kahlert Y, Khuder SA, Kohl M, Li J, Li L, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z, Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, Miclaus K, Moffitt RA, Montaner D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP, Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, Riccadonna S, Roter AH, Samuelson FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S, Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY, Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M, Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri RK, Scherf U, Tong W, Wolfinger RD, MAQC . The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28(8):827-838, 8/2010. e-Pub 7/30/2010. PMCID: PMC3315840.
25. Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 121(2):301-9, 6/2010. e-Pub 7/15/2009. PMID: 19603265.
26. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9(5):1120-7, 5/2010. e-Pub 4/27/2010. PMID: 20423993.
27. Hess KR, Wei C. Learning Curves in Classification With Microarray Data. Semin Oncol 37(1):65-68, 2/2010. PMID: 20172367.
28. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. e-Pub 1/27/2010. PMID: 20107864.
29. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-14, 1/2010. e-Pub 2/25/2009. PMID: 19241157.
30. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12(1):R5, 2010. e-Pub 1/11/2010. PMCID: PMC2880423.
31. Zhou YH, Hess KR, Raj VR, Yu L, Liu L, Yung AW, Linskey ME. Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomark Insights 5:153-68, 2010. e-Pub 12/22/2010. PMCID: PMC3018892.
32. Dupart JJ, Trent JC, Lee HY, Hess KR, Godwin AK, Taguchi T, Zhang W. Insulin-like growth factor binding proetin-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to anti-tumor effects of imatinib mesylate in vitro. Molecular Cancer 8(99), 11/2009.
33. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037-44, 11/2009. e-Pub 10/2009. PMID: 19801201.
34. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WKA, Liu TJ. Biomarkers of Disease: Cerebrospinal fluid Vascular Endothelial Growth factor (VEGF) and Stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM due to breast cancer, lung cancer and melanoma. J Neurooncol 94(2):229-34, 9/2009. e-Pub 3/2009. PMID: 19267183.
35. Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101(4):615-20, 8/18/2009. PMCID: PMC2736828.
36. Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer. J Clin Oncol 27(10):1592-1599, 4/2009. e-Pub 2/2009. PMCID: PMC2668967.
37. Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol 26(28):4679-83, 10/1/2008. PMID: 18662965.
38. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113(8):2046-52, 10/15/2008. PMID: 18756532.
39. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26(26):4311-8, 9/10/2008. PMCID: PMC2653122.
40. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26(27):4442-8, 9/20/2008. PMID: 18802157.
41. Harstad L, Hess KR, Groves MD. Prognostic Factors and Outcomes in Patients with Leptomeningeal Melanomatosis. Neuro Oncol, 8/2008. e-Pub 8/2008. PMID: 18708343.
42. Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, Sawaya R, Hess KR, Mills GB, Kawamura H, Hashimoto Y, Urata Y, Fujiwara T, Kondo S. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 15(17):1233-9, 6/26/2008. e-Pub 6/26/2008. PMID: 18580968.
43. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89-97, 6/2008. e-Pub 6/2008. PMID: 18581057.
44. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208-15, 4/2008. PMID: 18316473.
45. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216-22, 4/2008. PMID: 18314417.
46. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-23, 3/10/2008. PMID: 18323556.
47. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-81, 3/2008. PMID: 18250347.
48. Aoki H, Kondo Y, Aldape K, Yamamoto A, Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K, Shinojima N, Shingu T, Tamada Y, Zhang L, Conrad C, Bogler O, Mills G, Sawaya R, Kondo S. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy 4(4). e-Pub 2/2008. PMID: 18259115.
49. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD, Prados MD. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13(24):7401-6, 12/15/2007. PMID: 18094423.
50. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110(10):2186-90, 11/15/2007. PMID: 17896785.
51. Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, Hess KR, Aldape KD, Kondo S, Kumar R, Kondo Y. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res 13(22 Pt 1):6603-9, 11/2007. PMID: 18006760.
52. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 13(20):6080-6, 10/2007. PMID: 17947471.
53. Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR, Sawaya R, Mills GB, Gilchrest BA, Kondo S. Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J 21(11):2918-30, 9/2007. e-Pub 4/20/2007. PMID: 17449721.
54. Jiang R, Choi W, Khan A, Hess K, Gerner EW, Casero RA, Yung WK, Hamilton SR, Zhang W. Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma. Int J Oncol 31(2):431-40, 8/2007. PMID: 17611701.
55. Faria SC, Ng CS, Hess KR, Phongkitkarun S, Szejnfeld J, Daliani D, Charnsangavej C. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol 189(2):378-85, 8/2007. PMID: 17646464.
56. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18(5):874-80, 5/2007. e-Pub 2/2007. PMID: 17293601.
57. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26(17):2435-44, 4/12/2007. e-Pub 10/16/2006. PMID: 17043651.
58. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3):271-7, 2/2007. e-Pub 9/22/2006. PMID: 17031561.
59. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13(1):234-40, 1/1/2007. PMID: 17200360.
60. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3):203-11, 2007. PMID: 17329190.
61. Levin VA, Ictech S, Hess KR. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer 7:106, BMC Cancer, 2007. e-Pub 2007. PMID: 17587447.
62. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer 107(11):2576-80, 12/1/2006. PMID: 17075877.
63. Armstrong T, Cohen MZ, Hess KR, Manning R, Lee EL, Tamayo G, Baumgartner K, Min SJ, Yung A, Gilbert M. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage 32(2):148-54, 8/2006. PMID: 16877182.
64. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. J Clin Oncol 24(25):4107-15, 8/2006. PMID: 16908934.
65. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 30(5):657-64, 5/2006. PMID: 16699322.
66. Ito H, Aoki H, Kühnel F, Kondo Y, Kubicka S, Wirth T, Iwado E, Iwamaru A, Fujiwara K, Hess KR, Lang FF, Sawaya R, Kondo S. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 98(9):625-36, 5/2006. PMID: 16670388.
67. Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 78(1):85-90, 5/2006. e-Pub 11/29/2005. PMID: 16391896.
68. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8(2):189-93, 4/2006. e-Pub 3/13/2006. PMCID: PMC1871932.
69. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer 106(7):1624-33, 4/2006. PMID: 16518827.
70. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80(1):83-90, 4/2006. PMID: 16639492.
71. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24(11):1720-8, 4/2006. PMID: 16520463.
72. Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol 24(10):1627-32, 4/2006. PMID: 16575014.
73. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res 12(6):1721-7, 3/2006. PMID: 16551855.
74. Lecocke M, Hess KR. An Empirical Study of Univariate and Genetic Algorithm-Based Feature Selection in Binary Classification with Microarray Data. Cancer Informatics 2:313-327, 2006. PMID: Not in Pub Med.
75. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. J Clin Oncol 24(26):4236-4244, 2006. PMID: 16896004.
76. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer 12(4):1059-69, 12/2005. PMID: 16322343.
77. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23(33):8331-9, 11/2005. PMID: 16293864.
78. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104(7):1468-77, 10/1/2005. PMID: 16088966.
79. Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol 7(4):485-94, 10/2005. PMID: 16212813.
80. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-85, 8/2005. PMID: 16115903.
81. Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn 7(3):357-67, 8/2005. PMID: 16049308.
82. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD, Prados MD. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23(4):357-61, 8/2005. PMID: 16012795.
83. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 102(23):8315-20, 6/2005. PMID: 15914550.
84. Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 103(12):2485-90, 6/2005. PMID: 15861417.
85. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 23(13):3094-103, 5/2005. PMID: 15860869.
86. Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K, Hess KR, Gumin J, Lang F, Yung WK. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol 71(3):223-9, 2/2005. PMID: 15735909.
87. Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, Zhang W, Fidler IJ, Chiao PJ. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11(2 Pt 1):440-9, Nov-Dec, 1/2005. PMID: 15701826.
88. Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF. Mechanisms of action of rapamycin in gliomas. Neuro Oncol 7(1):1-11, Nov-Dec, 2005. PMID: 15701277.
89. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol 15(12):1731-7, Nov-Dec, 12/2004. PMID: 15550577.
90. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22(4):459-66, 11/2004. PMID: 15292716.
91. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer 101(10):2293-9, Nov-Dec, 11/2004. PMID: 15476282.
92. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22(4):427-35, 11/2004. PMID: 15292713.
93. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21):4282-9, Nov-Dec, 11/2004. PMID: 15514370.
94. See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol 6(3):253-8, Nov-Dec, 7/2004. PMID: 15279718.
95. Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer 101(1):58-65, Nov-Dec, 7/2004. PMID: 15221989.
96. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 6/2004. PMID: 15136595.
97. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239(6):818-25; discussion 825-7, 6/2004. PMCID: PMC1356290.
98. Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, Adatto P, Hess K, Ali-Osman F, Groves M, Yung AW, Levin VA, Wei Q, Bondy M. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 10(8):2618-25, 4/2004. PMID: 15102663.
99. Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer 100(8):1712-6, 4/2004. PMID: 15073861.
100. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, Sawaya R. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 10(1 Pt 1):212-21, 2004. PMID: 14734472.
101. Schold SC, Kokkinakis DM, Chang SM, Berger MS, Hess KR, Schiff D, Robins HI, Mehta MP, Fink KL, Davis RL, Prados MD. O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol 6(1):28-32, Nov-Dec, 2004. PMID: 14769137.
102. Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J, Kuhn J. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 6(1):44-54, Nov-Dec, 2004. PMID: 14769140.
103. Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC, Schold SC. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol 6(1):33-7, Nov-Dec, 2004. PMID: 14769138.
104. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9(11):4247-54, Nov-Dec, 9/2003. PMID: 14519652.
105. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9(9):3369-75, Nov-Dec, 8/2003. PMID: 12960124.
106. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9(7):2406-15, 7/2003. PMID: 12855612.
107. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M, Prados M. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21(12):2305-11, Nov-Dec, 6/2003. PMID: 12805331.
108. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-71, Nov-Dec, 6/2003. PMID: 12784330.
109. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5(2):89-95, Nov-Dec, 4/2003. PMID: 12672280.
110. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 9(3):955-60, Nov-Dec, 3/2003. PMID: 12631592.
111. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1):105-18, Nov-Dec, 3/2003. PMID: 12611463.
112. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981-90, Nov-Dec, 3/2003. PMID: 12631596.
113. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65(3):259-66, Nov-Dec, 2003. PMID: 14657600.
114. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8(6):461-8, Nov-Dec, 11/2002. PMID: 12500855.
115. Kim S, Dougherty ER, Shmulevich I, Hess KR, Hamilton SR, Trent JM, Fuller GN, Zhang W. Identification of combination gene sets for glioma classification. Mol Cancer Ther 1(13):1229-36, 11/2002. PMID: 12479704.
116. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20(18):3804-14, 9/2002. PMID: 12228200.
117. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20(18):3792-803, 9/2002. PMID: 12228199.
118. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 95(5):1120-6, 9/2002. PMID: 12209699.
119. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg 236(3):376-84; discussion 384-5, 9/2002. PMCID: PMC1422591.
120. Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 53(1):58-66, 5/2002. PMID: 12007942.
121. Robins HI, Chang SM, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn JG, Cloughesy T, Junck L, Mehta M. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol 4(2):109-14, 4/2002. PMCID: PMC1920656.
122. Shmulevich I, Hunt K, El-Naggar A, Taylor E, Ramdas L, Labordé P, Hess KR, Pollock R, Zhang W. Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. Cancer 94(7):2069-75, 4/2002. PMID: 11932911.
123. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20(5):1383-8, 3/2002. PMID: 11870183.
124. Winnerkvist A, Bartoli S, Iliopoulos DC, Hess KR, Miller CC, Safi HJ. Spinal cord protection during aortic cross clamping: retrograde venous spinal cord perfusion, distal aortic perfusion, and cerebrospinal fluid drainage. Scand Cardiovasc J 36(1):6-10, 2/2002. PMID: 12018769.
125. Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest 20(7-8):948-54, 2002. PMID: 12449727.
126. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 5(4):208-12, 2002. PMID: 12491078.
127. Herrera CA, Xu L, Bucana CD, Silva el VG, Hess KR, Gershenson DM, Fidler IJ. Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol 20(1):5-13, 2002. PMID: 11743636.
128. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 12(1):108-16, 2002. PMID: 11771519.
129. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190-8, 8/2001. PMID: 11780887.
130. Hess KR, Fuller GN, Rhee CH, Zhang W. Statistical pattern analysis of gene expression profiles for glioblastoma tissues and cell lines. Int J Mol Med 8(2):183-8, 8/2001. PMID: 11445872.
131. Pisters PW, Hudec WA, Hess KR, Lee JE, Vauthey JN, Lahoti S, Raijman I, Evans DB. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 234(1):47-55, 7/2001. PMID: 11420482.
132. Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol 3(3):167-73, 7/2001. PMCID: PMC1920617.
133. Munden RF, Hess KR. "Ditzels" on chest CT: survey of members of the Society of Thoracic Radiology. AJR Am J Roentgenol 176(6):1363-9, 6/2001. PMID: 11373192.
134. Gutman H, Hess KR, Kokotsakis JA, Ross MI, Guinee VF, Balch CM. Surgery for abdominal metastases of cutaneous melanoma. World J Surg 25(6):750-8, 6/2001. PMID: 11376411.
135. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8(2):123-32, 3/2001. PMID: 11258776.
136. Hill LR, Hess KR, Stephens LC, Price RE, Gray KN. Correlation of kidney weight and volume and selected skeletal parameters to sex in the adult rhesus monkey (Macaca mulatta). J Med Primatol 30(1):56-60, 2/2001. PMID: 11396864.
137. Kozuch P, Hoff PM, Hess K, Adams J, Newman RA, Lee F, Pazdur R. Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer 91(4):815-21, 2/2001. PMID: 11241251.
138. Baggerly KA, Coombes KR, Hess KR, Stivers DN, Abruzzo LV, Zhang W. Identifying differentially expressed genes in cDNA microarray experiments. J Comput Biol 8(6):639-59, 2001. PMID: 11747617.
139. Evans DB, Wolff RA, Hess KR. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg 232(5):727, 11/2000. PMID: 11066157.
140. Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 17(5):963-9, 11/2000. PMID: 11029499.
141. Meric F, Milas M, Hunt KK, Hess KR, Pisters PW, Hildebrandt G, Patel SR, Benjamin RS, Plager C, Papadopolous NE, Burgess MA, Pollock RE, Feig BW. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 18(19):3378-83, 10/2000. PMID: 11013278.
142. Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA PJ, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6(10):3878-84, 10/2000. PMID: 11051233.
143. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3):646-50, 2/2000. PMID: 10653880.
144. Lee JJ, Hess KR, Dubin JA. Extensions and applications of event charts. The American Statistician 54:63-70, 2000. PMID: Not in Pub Med.
145. Anderlik MR, Pentz RD, Hess KR. Revisiting the truth-telling debate: a study of disclosure practices at a major cancer center. J Clin Ethics 11(3):251-9, 2000. PMID: 11127639.
146. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5(11):3403-10, 11/1999. PMID: 10589751.
147. Hess KR, Serachitopol DM, Brown BW. Hazard function estimators: a simulation study. Stat Med 18(22):3075-88, 11/1999. PMID: 10544307.
148. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK. Response and progression in recurrent malignant glioma. Neuro Oncol 1(4):282-8, 10/1999. PMID: 11550320.
149. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59(17):4228-32, May-Jun, 9/1999. PMID: 10485462.
150. Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45(1):127-35, 8/1999. PMID: 10477016.
151. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572-8, May-Jun, 8/1999. PMID: 10561324.
152. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg 3(3):263-77, May-Jun, 5/1999. PMID: 10481119.
153. Rhee CH, Hess K, Jabbur J, Ruiz M, Yang Y, Chen S, Chenchik A, Fuller GN, Zhang W. cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines. Oncogene 18(17):2711-7, 4/1999. PMID: 10348345.
154. Hill LR, Hess KR, Stephens LC, Tinkey PT, Price RE. Comparison of kidney weight and volume to selected anatomical parameters in the adult female rhesus monkey (Macaca mulatta). J Med Primatol 28(2):67-72, 4/1999. PMID: 10431696.
155. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59(8):1820-4, 4/1999. PMID: 10213484.
156. Sigurdson AJ, Bondy ML, Hess KR, Toms SA, Kyritsis AP, Gu J, Wang LE, Wang X, Adatto P, Bruner JL, Yung WK, Levin VA, Wei Q. Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res 4(12):3031-5, 12/1998. PMID: 9865917.
157. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WK, Steck PA. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 4(10):2447-54, 10/1998. PMID: 9796977.
158. Ritter AM, Hess KR, McLendon RE, Langford LA. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol 40(1):51-7, 10/1998. PMID: 9874186.
159. Kattan MW, Hess KR, Beck JR. Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcomes theoretical limitations of Cox proportional hazards regression. Comput Biomed Res 31(5):363-73, 10/1998. PMID: 9790741.
160. Rumana CS, Hess KR, Shi WM, Sawaya R. Metastatic brain tumors with dural extension. J Neurosurg 89(4):552-8, 10/1998. PMID: 9761048.
161. Hoque A, Sigurdson AJ, Burau KD, Humphrey HE, Hess KR, Sweeney AM. Cancer among a Michigan cohort exposed to polybrominated biphenyls in 1973. Epidemiology 9(4):373-8, 7/1998. PMID: 9647899.
162. Svensson LG, Hess KR, D'Agostino RS, Entrup MH, Hreib K, Kimmel WA, Nadolny E, Shahian DM. Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. Ann Thorac Surg 66(1):132-8, 7/1998. PMID: 9692452.
163. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 16(6):2105-12, 6/1998. PMID: 9626210.
164. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, Wildrick DM. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42(5):1044-55; discussion 1055-6, 5/1998. PMID: 9588549.
165. Wong ET, Jackson EF, Hess KR, Schomer DF, Hazle JD, Kyritsis AP, Jaeckle KA, Yung WK, Levin VA, Leeds NE. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 50(3):777-81, 3/1998. PMID: 9521274.
166. Ali-Osman F, Brunner JM, Kutluk TM, Hess K. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 3(12 Pt 1):2253-61, 12/1997. PMID: 9815622.
167. Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, Cleary KR, Skibber JM. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 3(10):1685-90, 10/1997. PMID: 9815551.
168. Pieper DR, Hess KR, Sawaya RE. Role of surgery in the treatment of brain metastases in patients with breast cancer. Ann Surg Oncol 4(6):481-90, 9/1997. PMID: 9309337.
169. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 15(10):1114-22, 7/1997. PMID: 9269055.
170. Meterissian SH, Skibber JM, Giacco GG, el-Naggar AK, Hess KR, Rich TA. Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery 121(5):479-87, 5/1997. PMID: 9142144.
171. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordońez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma. J Clin Oncol 15(5):2056-66, 5/1997. PMID: 9164218.
172. Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med 157(9):970-6, 5/1997. PMID: 9140267.
173. Strom SS, Hess KR, Sigurdson AJ, Spitz MR, Liang JC. Evaluation of sister chromatid exchange and chromosome breaks in a cohort of untreated Hodgkin's disease patients. Cancer Epidemiol Biomarkers Prev 6(4):291-3, 4/1997. PMID: 9107435.
174. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15(3):1063-70, 3/1997. PMID: 9060546.
175. Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res 2(9):1489-97, 9/1996. PMID: 9816325.
176. Bindal AK, Bindal RK, Hess KR, Shiu A, Hassenbusch SJ, Shi WM, Sawaya R. Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 84(5):748-54, 5/1996. PMID: 8622147.
177. Sawaya R, Ligon BL, Bindal AK, Bindal RK, Hess KR. Surgical treatment of metastatic brain tumors. J Neurooncol 27(3):269-77, Jan-Feb, 3/1996. PMID: 8847561.
178. Safi HJ, Hess KR, Randel M, Iliopoulos DC, Baldwin JC, Mootha RK, Shenaq SS, Sheinbaum R, Greene T. Cerebrospinal fluid drainage and distal aortic perfusion: reducing neurologic complications in repair of thoracoabdominal aortic aneurysm types I and II. J Vasc Surg 23(2):223-8; discussion 229, Jan-Feb, 2/1996. PMID: 8637099.
179. Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1(12):1617-22, Jan-Feb, 12/1995. PMID: 9815964.
180. Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH. Reoperation for recurrent metastatic brain tumors. J Neurosurg 83(4):600-4, Jan-Feb, 10/1995. PMID: 7674007.
181. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13(8):2094-103, Jan-Feb, 8/1995. PMID: 7636553.
182. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14(15):1707-23, Jan-Feb, 8/1995. PMID: 7481205.
183. Safi HJ, Iliopoulos DC, Gopinath SP, Hess KR, Asimacopoulos PJ, Bartoli S, Raskin SA, Shaibani AT, Leveque CM, Yawn DH. Retrograde cerebral perfusion during profound hypothermia and circulatory arrest in pigs. Ann Thorac Surg 59(5):1107-12, Jan-Feb, 5/1995. PMID: 7733705.
184. Hawkins JL, Hess KR, Kubicek MA, Joyce TH, Morrow DH. A reevaluation of the association between instrument delivery and epidural analgesia. Reg Anesth 20(1):50-6, Jan-Feb, 1995. PMID: 7727329.
185. Younis GA, Sawaya R, DeMonte F, Hess KR, Albrecht S, Bruner JM. Aggressive meningeal tumors: review of a series. J Neurosurg 82(1):17-27, Jan-Feb, 1995. PMID: 7815129.
186. Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 32(10):2468-73, Mar-Apr, 10/1994. PMID: 7814484.
187. Safi HJ, Bartoli S, Hess KR, Shenaq SS, Viets JR, Butt GR, Sheinbaum R, Doerr HK, Maulsby R, Rivera VM. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: the role of cerebral spinal fluid drainage and distal aortic perfusion. J Vasc Surg 20(3):434-44; discussion 442-3, Mar-Apr, 9/1994. PMID: 8084037.
188. Svensson LG, Hess KR, Coselli JS, Safi HJ. Influence of segmental arteries, extent, and atriofemoral bypass on postoperative paraplegia after thoracoabdominal aortic operations. J Vasc Surg 20(2):255-62, Mar-Apr, 8/1994. PMID: 8040949.
189. Ritter AM, Sawaya R, Hess KR, Levin VA, Bruner JM. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme. Neurosurgery 35(2):192-8; discussion 198, Mar-Apr, 8/1994. PMID: 7969825.
190. Guinee VF, Olsson H, Möller T, Hess KR, Taylor SH, Fahey T, Gladikov JV, van den Blink JW, Bonichon F, Dische S. Effect of pregnancy on prognosis for young women with breast cancer. Lancet 343(8913):1587-9, Mar-Apr, 6/1994. PMID: 7911917.
191. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12(6):1272-80, Mar-Apr, 6/1994. PMID: 8201389.
192. Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 13(10):1045-62, Mar-Apr, 5/1994. PMID: 8073200.
193. Shiono M, Noon GP, Hess KR, Takatani S, Sasaki T, Orime Y, Young JB, Nosé Y, DeBakey ME. Anatomic constraints for a total artificial heart in orthotopic heart transplant recipients. J Heart Lung Transplant 13(2):250-62, Mar-Apr, 3/1994. PMID: 8031808.
194. Barnes G, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1(1):73-8, 1994. PMID: 7834432.
195. Vybiral T, Glaeser DH, Morris G, Hess KR, Yang K, Francis M, Pratt CM. Effects of low-dose transdermal scopolamine on heart rate variability in acute myocardial infarction. J Am Coll Cardiol 22(5):1320-6, 11/1993. PMID: 8227787.
196. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Variables predictive of outcome in 832 patients undergoing repairs of the descending thoracic aorta. Chest 104(4):1248-53, 10/1993. PMID: 8404201.
197. Vybiral T, Glaeser DH, Goldberger AL, Rigney DR, Hess KR, Mietus J, Skinner JE, Francis M, Pratt CM. Conventional heart rate variability analysis of ambulatory electrocardiographic recordings fails to predict imminent ventricular fibrillation. J Am Coll Cardiol 22(2):557-65, 8/1993. PMID: 8335829.
198. Svensson LG, Crawford ES, Hess KR, Coselli JS, Raskin S, Shenaq SA, Safi HJ. Deep hypothermia with circulatory arrest: Determinants of stroke and early mortality in 656 patients. J Thorac Cardiovasc Surg 106(1):19-31, 7/1993. PMID: 8321002.
199. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 17(2):357-70, 2/1993. PMID: 8433431.
200. Nudelman HB, Herbrich KE, Hess KR, Hoyt BD, Rosenfield DB. A model of the phonatory response time of stutterers and fluent speakers to frequency-modulated tones. J Acoust Soc Am 92(4 Pt 1):1882-8, 10/1992. PMID: 1401532.
201. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Composite valve graft replacement of the proximal aorta: Comparison of techniques in 348 patients. Ann Thorac Surg 54(3):427-39, 9/1992. PMID: 1510509.
202. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Thoracoabdominal aortic aneurysms associated with celiac, superior mesenteric, and renal artery occlusive disease: Methods and analysis of results in 271 patients. J Vasc Surg 16(3):378-90, 9/1992. PMID: 1522640.
203. Svensson LG, Hess KR, Coselli JS, Safi HJ, Crawford ES. A prospective study of respiratory failure after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg 14(3):271-82, 9/1991. PMID: 1880835.
204. Staudacher RA, Hess KR, Harris SL, Abu-Khalil J, Heibig J. Percutaneous transluminal coronary angioplasty utilizing prolonged balloon inflations: Initial results and six-month follow-up. Cathet Cardiovasc Diagn 23(4):239-44, 8/1991. PMID: 1889077.
205. Crawford ES, Hess KR, Cohen ES, Coselli JS, Safi HJ. Ruptured aneurysm of the descending thoracic and thoracoabdominal aorta: Analysis according to size and treatment. Ann Surg 213(5):417-26, 5/1991. PMID: 2025061.
206. Crawford ES, Svensson LG, Hess KR, Shenaq SS, Coselli JS, Safi HJ, Mohindra PK, Rivera V. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg 13(1):36-46, 1991. PMID: 1987395.
207. Palacios QT, Jones MM, Hawkins JL, Adenwala JN, Longmire S, Hess KR, Skjonsby BS, Morrow DH, Joyce TH. Post-caesarean section analgesia: A comparison of epidural butorphanol and morphine. Can J Anaesth 38(1):24-30, 1991. PMID: 1989736.
208. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Dissection of the aorta and dissecting aortic aneurysms. Improving early and long-term surgical results. Circulation 82(5 Suppl):IV24-38, 11/1990. PMID: 2225411.
209. Jeroudi MO, Kleiman NS, Minor ST, Hess KR, Lewis JM, Winters WL, Raizner AE. Percutaneous transluminal coronary angioplasty in octogenarians. Ann Intern Med 113(6):423-8, 9/1990. PMID: 2386335.
210. Crawford ES, Coselli JS, Svensson LG, Safi HJ, Hess KR. Diffuse aneurysmal disease (chronic aortic dissection, Marfan, and mega aorta syndromes) and multiple aneurysm: Treatment by subtotal and total aortic replacement emphasizing the elephant trunk operation. Ann Surg 211(5):521-37, 5/1990. PMID: 2339914.
211. Crawford ES, Svensson LG, Coselli JS, Safi HJ, Hess KR. Surgical treatment of aneurysm and/or dissection of the ascending aorta, transverse aortic arch, and ascending aorta and transverse aortic arch: Factors influencing survival in 717 patients. J Thorac Cardiovasc Surg 98(5 Pt 1):659-74, 11/1989. PMID: 2811404.
212. Svensson LG, Coselli JS, Safi HJ, Hess KR, Crawford ES. Appraisal of adjuncts to prevent acute renal failure after surgery on the thoracic or thoracoabdominal aorta. J Vasc Surg 10(3):230-9, 9/1989. PMID: 2778885.
213. Svensson LG, Crawford ES, Coselli JS, Safi HJ, Hess KR. Impact of cardiovascular operation on survival in the Marfan patient. Circulation 80(3 Pt 1):I233-42, 9/1989. PMID: 2766531.
214. Ostojic MC, Young JB, Hess KR. Prediction of left ventricular ejection fraction using a unique method of chest x-ray and electrocardiographic analysis: A noninvasive index of cardiac performance based on the concept of heart volume and mass interrelationship. Am Heart J 117(3):590-8, 3/1989. PMID: 2919538.
215. Mizrahi EM, Patel VM, Crawford ES, Coselli JS, Hess KR. Hypothermic-induced electrocerebral silence, prolonged circulatory arrest, and cerebral protection during cardiovascular surgery. Electroencephalogr Clin Neurophysiol 72(1):81-5, 1989. PMID: 2464479.
216. Crawford ES, Svensson LG, Coselli JS, Safi HJ, Hess KR. Aortic dissection and dissecting aortic aneurysms. Ann Surg 208(3):254-73, 9/1988. PMID: 3421752.
217. Coselli JS, Crawford ES, Beall AC, Mizrahi EM, Hess KR, Patel VM. Determination of brain temperatures for safe circulatory arrest during cardiovascular operation. Ann Thorac Surg 45(6):638-42, 6/1988. PMID: 3377576.
218. Crawford ES, Mizrahi EM, Hess KR, Coselli JS, Safi HJ, Patel VM. The impact of distal aortic perfusion and somatosensory evoked potential monitoring on prevention of paraplegia after aortic aneurysm operation. J Thorac Cardiovasc Surg 95(3):357-67, 3/1988. PMID: 3343847.
219. Griffin JC, Schuenemeyer TD, Hess KR, Glaeser D, Anderson BJ, Romans E, Jenkins MA, Nielsen AP. Pacemaker follow-up: Its role in the detection and correction of pacemaker system malfunction. Pacing Clin Electrophysiol 9(3):387-91, 5/1986. PMID: 2423980.
220. Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, Norton HJ, Glaeser DH. Thoracoabdominal aortic aneurysms: Preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg 3(3):389-404, 3/1986. PMID: 3951025.

Invited Articles

1. Hess KR. Statistical issues in clinical trial design. Curr Oncol Rep 9(1):55-9, 2007. PMID: 17164048.
2. Hess KR, Zhang W, Baggerly KA, Stivers DN, Coombes KR. Microarrays: handling the deluge of data and extracting reliable information. Trends Biotechnol 19(11):463-8, 11/2001. PMID: 11602311.
3. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42(3):227-31, 5/1999. PMID: 10433106.

Editorials

1. Crawford ES, Hess KR. Abdominal aortic aneurysm. N Engl J Med 321(15):1040-2, 1989. PMID: 2674718.
Other Articles
1. ZHong M and Hess KR. Mean Survival Time from Right Censored Data. COBRA Preprint Series(Article 66), 12/2009.
2. Hess KR. Coming to Grips with Microarray Data Analysis. Trends in Biotechnology 20(5):226-227, 2002.
3. Hess, KR, Pagel, W, Browner, WS. Publishing and Presenting Clinical Research. 131(8):636, 1999.

Book Chapters

1. Hess KR. Statistical Considerations in the Design and Analysis of Microarray Experiments. In: Genomic and Molecular Neuro-Oncology. Ed(s) W Zhang, GN Fuller. Jones & Bartlett Publishers, 2003.
2. Pusztai L, Symmans WF, Buchholz TA, Stec J, Ayers M, Clark E, Meric F, Stivers D, Hess KR. Application of DNA microarray technology to clinical biopsies of breast cancer. In: Computational and Statistical Approaches to Genomics. Ed(s) W Zhang, I Shmulevich. Kluwer Academic Publishers: Boston, 2002.
3. Fuller G, Hess KR, Wang HW, Bruner J, Zhang. Identification of glioma marker genes by cDNA microarray and validation by tissue array. In: Computational and Statistical Approaches to Genomics. Ed(s) W Zhang, I Shmulevich. Kluwer Academic Publishers: Boston, 2002.
4. Baggerly K, Coombes K, Hess KR, Stivers D, Abbruzzo L, and Zhang W. Studentizing microarray data. In: Computational and Statistical Approaches to Genomics. Ed(s) W Zhang, I Shmulevich. Kluwer Academic Publishers: Boston, 2002.

Letters to the Editor

1. Hess RK. Statistical design considerations in animal studies published recently in cancer research. Cancer Res 71(2):625, 1/2011. PMID: 21239476.
2. Evans DB, Hess KR, Pisters PW. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg 236(5):694; author reply 694-6, 11/2002. PMID: 12409677.
3. Hess KR, Abbruzzese JL. Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol 19(15):3445-6, 8/2001. PMID: 11481348.
4. Pentz RD, Young LN, Amos CI, Hess KR, Wei Q, Anderlik MR. Informed consent for tissue research. JAMA 282(17):1625, 11/1999. PMID: 10553787.
5. Hess KR, Wong ET, Yung WK. Assessing response to chemotherapy in malignant glioma: the role of steroids. Neurology 50(4):1197; discussion 1197-8, 4/1998. PMID: 9566439.
6. Hess, KR, Skibber, JM, Giacco, GG. Misuse of multivariate analysis-reply. Surgery 123:114-115, 1998.
7. Bindal RK, Bindal AK, Hess KR. Survival after radiosurgery for brain metastasis: regarding Buatti et al. Int J Radiat Oncol Biol Phys 36(2):523, 9/1996. PMID: 8892480.
8. Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR. Are time or intensity factors important to the definition of metastases of unknown origin? J Natl Cancer Inst 88(7):462-3, Jan-Feb, 4/1996. PMID: 8618241.
9. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 73(10):1533-1535, 1994. PMID: 8490842.
10. Guinee VF, Hess KR. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 72(7):2291-2, 10/1993. PMID: 8104093.
11. Hess KR. Abdominal aortic aneurysm measurement: A critique of methods for comparison studies. Invest Radiol 28(11):787-788, 1993. PMID: 1464517.
12. Hess KR. Confidence intervals and survival estimates. J Thorac Cardiovasc Surg 102(3):456-9, 9/1991. PMID: 1881186.

Grant & Contract Support

Title: SPORE in Brain Cancer - Biostatistics Core (PC-C)
Funding Source: NIH/NCI
Role: Core Director
Principal Investigator: Lang
Duration: 9/17/2013 - 8/31/2018
 
Title: Cancer Center Support Grant - Biostatistics Shared Resource (PPSR-21)
Funding Source: NIH/NCI
Role: Statistician
Principal Investigator: Ronald DePinho
Duration: 7/1/2013 - 6/30/2018
 
Title: Development and validation of comprehensive prognosis models for malignant gliomas
Funding Source: NIH/NCI (Subcontract from University of California)
Role: Co-Investigator
Principal Investigator: Yi-hong Zhou
Duration: 7/1/2012 - 6/30/2017
 
Title: Strategy for improving risk-adapted therapy in diffuse large B-Cell lymphoma
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Timothy McDonnell
Duration: 7/1/2012 - 6/30/2017
 
Title: A Novel Preoperative Platform in Pancreatic Cancer for Mechanistic Studies
Funding Source: Lustgarten Foundation for Pancreatic Research
Role: Co-Investigator
Principal Investigator: Gauri Varadhachary
Duration: 5/1/2011 - 10/31/2014
 
Title: Dissecting Glioma Genesis through a Glial-Specific Mouse Model
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Wei Zhang
Duration: 9/3/2010 - 7/31/2015
 
Title: Oncogene cooperation in glioma genesis
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Wei Zhang
Duration: 8/1/2010 - 6/30/2015
 
Title: UPRCCC/MDACC: Partnership for Excellence in Cancer Research (PC-D)
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Raymond DuBois
Duration: 9/29/2008 - 8/31/2012
 
Title: SPORE in Pancreatic Cancer (PC-B)
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: James L. Abbruzzese
Duration: 9/30/2003 - 6/30/2010
 
Title: Characterization of Leiomyosarcoma and GIST by Genomics
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Wei Zhang
Duration: 7/1/2003 - 6/30/2006
 
Title: Conditional Replicating Adenovirus for Glioma Treatment
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Juan Fueyo
Duration: 8/15/2002 - 7/31/2007
 
Title: Molecular Epidemiology of Gliomas
Funding Source: NIH/NCI
Role: Biostatistician
Principal Investigator: Melissa Bondy
Duration: 9/30/2000 - 8/31/2007

Last updated: 7/24/2014